144 related articles for article (PubMed ID: 8540726)
1. In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.
Dhople AM; Ibanez MA
Antimicrob Agents Chemother; 1995 Sep; 39(9):2116-9. PubMed ID: 8540726
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
Dhople AM; Namba K
J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
[TBL] [Abstract][Full Text] [Related]
3. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1995 Apr; 35(4):463-71. PubMed ID: 7628981
[TBL] [Abstract][Full Text] [Related]
4. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA; Gardner GD
Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
Dhople AM; Dimova V
Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1993 Sep; 32(3):445-51. PubMed ID: 8262866
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.
Baltch AL; Smith RP; Ritz W
Antimicrob Agents Chemother; 1995 Aug; 39(8):1661-6. PubMed ID: 7486896
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
Dhople AM
Int J Antimicrob Agents; 2001 Jan; 17(1):57-61. PubMed ID: 11137650
[TBL] [Abstract][Full Text] [Related]
9. [Tympanostomy tube otorrhea: microbiological epidemiology, pathogen susceptibility to local antibiotics and bactericidal power of the rifamycin-olfloxacin combination].
François M; Mariani-Kurkdjian P; Doit C; Benzekri P; Bingen E; Macé JG
Ann Otolaryngol Chir Cervicofac; 2001 Oct; 118(5):278-82. PubMed ID: 11845035
[TBL] [Abstract][Full Text] [Related]
10. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Dhople AM; Namba K
Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae.
Franzblau SG
Antimicrob Agents Chemother; 1991 Jun; 35(6):1232-4. PubMed ID: 1929269
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
Dhople AM
Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
[TBL] [Abstract][Full Text] [Related]
14. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Sato K; Ogasawara K; Akaki T; Tomioka H
Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Sato K; Tomioka H; Akaki T; Kawahara S
Int J Antimicrob Agents; 2000 Sep; 16(1):25-9. PubMed ID: 11185410
[TBL] [Abstract][Full Text] [Related]
16. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
Indian J Lepr; 1995; 67(4):375-82. PubMed ID: 8849914
[TBL] [Abstract][Full Text] [Related]
17. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae.
Cambau E; Perani E; Guillemin I; Jamet P; Ji B
Lancet; 1997 Jan; 349(9045):103-4. PubMed ID: 8996430
[No Abstract] [Full Text] [Related]
18. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
Rastogi N; Goh KS; Bryskier A; Devallois A
Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
[TBL] [Abstract][Full Text] [Related]
20. [In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Gidoh M
Nihon Hansenbyo Gakkai Zasshi; 2007 Feb; 76(1):11-7. PubMed ID: 17315747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
